Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
This opportunity funds collaborative research projects to understand why cancer therapies cause long-lasting or delayed adverse side effects, and to translate that mechanism knowledge into prevention or mitigation strategies. Applicants may pursue clinical characterization and longitudinal phenotyping, including development or validation of endpoints such as biomarkers, imaging measures, and p…
Source
Dates
Eligibility
Keywords
Supporting Links
Documents
Similar Opportunities
-
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Institutes of Health
-
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
National Institutes of Health
-
Mission Boost Grants (MBG)
American Cancer Society
-
Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
National Institutes of Health
-
RFA: EDS Accelerator Award
American Cancer Society
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers